157 related articles for article (PubMed ID: 33758009)
1. Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction.
Shrestha P; Adepu S; Vivès RR; Masri RE; Klooster A; Kaptein F; Dam W; Bakker SJL; van Goor H; van de Sluis B; van den Born J
J Am Soc Nephrol; 2021 Jun; 32(6):1371-1388. PubMed ID: 33758009
[TBL] [Abstract][Full Text] [Related]
2. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
[TBL] [Abstract][Full Text] [Related]
3. Proteinuria converts hepatic heparan sulfate to an effective proprotein convertase subtilisin kexin type 9 enzyme binding partner.
Shrestha P; Yazdani S; Vivès RR; El Masri R; Dam W; van de Sluis B; van den Born J
Kidney Int; 2021 Jun; 99(6):1369-1381. PubMed ID: 33609572
[TBL] [Abstract][Full Text] [Related]
4. Heparan sulfate proteoglycans present PCSK9 to the LDL receptor.
Gustafsen C; Olsen D; Vilstrup J; Lund S; Reinhardt A; Wellner N; Larsen T; Andersen CBF; Weyer K; Li JP; Seeberger PH; Thirup S; Madsen P; Glerup S
Nat Commun; 2017 Sep; 8(1):503. PubMed ID: 28894089
[TBL] [Abstract][Full Text] [Related]
5. IL-13-driven alterations in hepatic cholesterol handling contributes to hypercholesterolemia in a rat model of minimal change disease.
Low LD; Lu L; Chan CY; Chen J; Yang HH; Yu H; Lee CGL; Ng KH; Yap HK
Clin Sci (Lond); 2020 Jan; 134(2):225-237. PubMed ID: 31934720
[TBL] [Abstract][Full Text] [Related]
6. Heparin Does Not Regulate Circulating Human PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) in a General Population-Brief Report.
Xia VQ; Ong CM; Zier LS; MacGregor JS; Wu AHB; Chorba JS
Arterioscler Thromb Vasc Biol; 2023 Feb; 43(2):352-358. PubMed ID: 36475702
[TBL] [Abstract][Full Text] [Related]
7. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
Galvan AM; Chorba JS
J Lipid Res; 2019 Jan; 60(1):71-84. PubMed ID: 30463987
[TBL] [Abstract][Full Text] [Related]
8. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations.
Sucajtys-Szulc E; Szolkiewicz M; Swierczynski J; Rutkowski B
Atherosclerosis; 2016 May; 248():17-26. PubMed ID: 26978583
[TBL] [Abstract][Full Text] [Related]
10. Acute UV irradiation increases heparan sulfate proteoglycan levels in human skin.
Jung JY; Oh JH; Kim YK; Shin MH; Lee D; Chung JH
J Korean Med Sci; 2012 Mar; 27(3):300-6. PubMed ID: 22379342
[TBL] [Abstract][Full Text] [Related]
11. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
Dong J; He M; Li J; Pessentheiner A; Wang C; Zhang J; Sun Y; Wang WT; Zhang Y; Liu J; Wang SC; Huang PH; Gordts PL; Yuan ZY; Tsimikas S; Shyy JY
JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33119548
[TBL] [Abstract][Full Text] [Related]
12. Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia.
Salaheldin TA; Godugu K; Bharali DJ; Fujioka K; Elshourbagy N; Mousa SA
Nanomedicine; 2022 Feb; 40():102480. PubMed ID: 34748962
[TBL] [Abstract][Full Text] [Related]
13. Hepatic syndecan-1 changes associate with dyslipidemia after renal transplantation.
Adepu S; Katta K; Tietge UJ; Kwakernaak AJ; Dam W; van Goor H; Dullaart RP; Navis GJ; Bakker SJ; van den Born J
Am J Transplant; 2014 Oct; 14(10):2328-38. PubMed ID: 25154787
[TBL] [Abstract][Full Text] [Related]
14. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P
Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure.
Sucajtys-Szulc E; Szolkiewicz M; Swierczynski J; Rutkowski B
Mol Cell Biochem; 2016 Jan; 411(1-2):281-7. PubMed ID: 26481479
[TBL] [Abstract][Full Text] [Related]
16. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
17. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
[TBL] [Abstract][Full Text] [Related]
18. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
19. Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice.
Foley EM; Gordts PLSM; Stanford KI; Gonzales JC; Lawrence R; Stoddard N; Esko JD
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2065-74. PubMed ID: 23846497
[TBL] [Abstract][Full Text] [Related]
20. High-salt diet induces dyslipidemia through the SREBP2/PCSK9 pathway in dahl salt-sensitive rats.
Ou-Yang YN; Deng FF; Wang YJ; Chen M; Yang PF; Yang Z; Tian Z
Biochimie; 2024 Jan; 216():34-45. PubMed ID: 37844755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
